Day

October 13, 2021
Pomalidomide (Pomalyst) in combination with bortezomib and dexamethasone (PVd) will be reimbursed on the PBS from 1 October for patients with relapsed or refractory  multiple myeloma who have received at least one prior treatment regimen including lenalidomide. According to distributor Bristol Myers Squibb, the thalidomide analogue was approved based on findings from the OPTIMISMM trial...
Continue Reading
People with blood cancers who are immunocompromised are now advised to have a third primary dose of COVID-19 vaccine with an mRNA vaccine. On 8 October the Australian Technical Advisory Group on Immunisation (ATAGI) recommended a booster third dose of vaccine as part of the primary course in individuals who are severely immunocompromised to address the risk...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand